vs
Axon Enterprise（AXON）与Insulet Corporation（PODD）财务数据对比。点击上方公司名可切换其他公司
Axon Enterprise的季度营收约是Insulet Corporation的1.0倍（$796.7M vs $783.7M），Insulet Corporation净利率更高（13.0% vs 0.3%，领先12.6%），Axon Enterprise同比增速更快（38.9% vs 31.2%），Axon Enterprise自由现金流更多（$155.4M vs $48.2M），过去两年Insulet Corporation的营收复合增速更高（33.2% vs 31.5%）
Axon Enterprise是总部位于美国亚利桑那州斯科茨代尔的企业，面向军队、执法部门及民用市场开发各类武器装备与相关技术产品，业务覆盖公共安全、国防及民用消费等多个领域，为不同用户群体提供适配的产品解决方案。
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
AXON vs PODD — 直观对比
营收规模更大
AXON
是对方的1.0倍
$783.7M
营收增速更快
AXON
高出7.8%
31.2%
净利率更高
PODD
高出12.6%
0.3%
自由现金流更多
AXON
多$107.2M
$48.2M
两年增速更快
PODD
近两年复合增速
31.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $796.7M | $783.7M |
| 净利润 | $2.7M | $101.6M |
| 毛利率 | 57.9% | 72.6% |
| 营业利润率 | -6.3% | 18.7% |
| 净利率 | 0.3% | 13.0% |
| 营收同比 | 38.9% | 31.2% |
| 净利润同比 | -98.0% | 0.9% |
| 每股收益（稀释后） | $0.02 | $1.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXONPODD
| Q4 25 | $796.7M | $783.7M | ||
| Q3 25 | $710.6M | $706.3M | ||
| Q2 25 | $668.5M | $649.1M | ||
| Q1 25 | $603.6M | $569.0M | ||
| Q4 24 | $573.4M | $597.5M | ||
| Q3 24 | $544.3M | $543.9M | ||
| Q2 24 | $504.1M | $488.5M | ||
| Q1 24 | $460.7M | $441.7M |
净利润AXONPODD
| Q4 25 | $2.7M | $101.6M | ||
| Q3 25 | $-2.2M | $87.6M | ||
| Q2 25 | $36.1M | $22.5M | ||
| Q1 25 | $88.0M | $35.4M | ||
| Q4 24 | $136.0M | $100.7M | ||
| Q3 24 | $67.0M | $77.5M | ||
| Q2 24 | $40.8M | $188.6M | ||
| Q1 24 | $133.2M | $51.5M |
毛利率AXONPODD
| Q4 25 | 57.9% | 72.6% | ||
| Q3 25 | 60.1% | 72.2% | ||
| Q2 25 | 60.4% | 69.7% | ||
| Q1 25 | 60.6% | 71.9% | ||
| Q4 24 | 60.5% | 72.1% | ||
| Q3 24 | 60.8% | 69.3% | ||
| Q2 24 | 60.3% | 67.7% | ||
| Q1 24 | 56.4% | 69.5% |
营业利润率AXONPODD
| Q4 25 | -6.3% | 18.7% | ||
| Q3 25 | -0.3% | 16.7% | ||
| Q2 25 | -0.2% | 18.7% | ||
| Q1 25 | -1.5% | 15.6% | ||
| Q4 24 | -2.6% | 18.3% | ||
| Q3 24 | 4.4% | 16.2% | ||
| Q2 24 | 6.5% | 11.2% | ||
| Q1 24 | 3.5% | 12.9% |
净利率AXONPODD
| Q4 25 | 0.3% | 13.0% | ||
| Q3 25 | -0.3% | 12.4% | ||
| Q2 25 | 5.4% | 3.5% | ||
| Q1 25 | 14.6% | 6.2% | ||
| Q4 24 | 23.7% | 16.9% | ||
| Q3 24 | 12.3% | 14.2% | ||
| Q2 24 | 8.1% | 38.6% | ||
| Q1 24 | 28.9% | 11.7% |
每股收益（稀释后）AXONPODD
| Q4 25 | $0.02 | $1.42 | ||
| Q3 25 | $-0.03 | $1.24 | ||
| Q2 25 | $0.44 | $0.32 | ||
| Q1 25 | $1.08 | $0.50 | ||
| Q4 24 | $1.68 | $1.38 | ||
| Q3 24 | $0.86 | $1.08 | ||
| Q2 24 | $0.53 | $2.59 | ||
| Q1 24 | $1.73 | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | — |
| 总债务越低越好 | $1.8B | $930.8M |
| 股东权益账面价值 | $3.2B | $1.5B |
| 总资产 | $7.0B | $3.2B |
| 负债/权益比越低杠杆越低 | 0.56× | 0.61× |
8季度趋势，按日历期对齐
现金及短期投资AXONPODD
| Q4 25 | $1.7B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $788.1M | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $968.9M | — | ||
| Q1 24 | $964.1M | — |
总债务AXONPODD
| Q4 25 | $1.8B | $930.8M | ||
| Q3 25 | $2.0B | $934.9M | ||
| Q2 25 | $2.0B | $939.0M | ||
| Q1 25 | $2.0B | $1.6B | ||
| Q4 24 | $680.3M | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
股东权益AXONPODD
| Q4 25 | $3.2B | $1.5B | ||
| Q3 25 | $3.0B | $1.4B | ||
| Q2 25 | $2.7B | $1.5B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $2.3B | $1.2B | ||
| Q3 24 | $2.1B | $1.1B | ||
| Q2 24 | $1.9B | $998.4M | ||
| Q1 24 | $1.8B | $790.7M |
总资产AXONPODD
| Q4 25 | $7.0B | $3.2B | ||
| Q3 25 | $6.7B | $3.0B | ||
| Q2 25 | $6.2B | $3.5B | ||
| Q1 25 | $6.1B | $3.5B | ||
| Q4 24 | $4.5B | $3.1B | ||
| Q3 24 | $4.0B | $3.0B | ||
| Q2 24 | $3.7B | $2.9B | ||
| Q1 24 | $3.6B | $2.6B |
负债/权益比AXONPODD
| Q4 25 | 0.56× | 0.61× | ||
| Q3 25 | 0.66× | 0.68× | ||
| Q2 25 | 0.73× | 0.64× | ||
| Q1 25 | 0.79× | 1.21× | ||
| Q4 24 | 0.29× | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $217.2M | $183.3M |
| 自由现金流经营现金流 - 资本支出 | $155.4M | $48.2M |
| 自由现金流率自由现金流/营收 | 19.5% | 6.2% |
| 资本支出强度资本支出/营收 | 7.8% | 17.2% |
| 现金转化率经营现金流/净利润 | 79.14× | 1.80× |
| 过去12个月自由现金流最近4个季度 | $75.1M | $377.7M |
8季度趋势，按日历期对齐
经营现金流AXONPODD
| Q4 25 | $217.2M | $183.3M | ||
| Q3 25 | $60.0M | $125.7M | ||
| Q2 25 | $-91.7M | $196.5M | ||
| Q1 25 | $25.8M | $63.8M | ||
| Q4 24 | $250.2M | $147.7M | ||
| Q3 24 | $91.3M | $98.5M | ||
| Q2 24 | $82.8M | $96.5M | ||
| Q1 24 | $-15.9M | $87.6M |
自由现金流AXONPODD
| Q4 25 | $155.4M | $48.2M | ||
| Q3 25 | $33.4M | $100.1M | ||
| Q2 25 | $-114.7M | $177.9M | ||
| Q1 25 | $932.0K | $51.5M | ||
| Q4 24 | $225.4M | $94.1M | ||
| Q3 24 | $64.8M | $71.8M | ||
| Q2 24 | $71.4M | $74.0M | ||
| Q1 24 | $-32.1M | $65.5M |
自由现金流率AXONPODD
| Q4 25 | 19.5% | 6.2% | ||
| Q3 25 | 4.7% | 14.2% | ||
| Q2 25 | -17.2% | 27.4% | ||
| Q1 25 | 0.2% | 9.1% | ||
| Q4 24 | 39.3% | 15.7% | ||
| Q3 24 | 11.9% | 13.2% | ||
| Q2 24 | 14.2% | 15.1% | ||
| Q1 24 | -7.0% | 14.8% |
资本支出强度AXONPODD
| Q4 25 | 7.8% | 17.2% | ||
| Q3 25 | 3.7% | 3.6% | ||
| Q2 25 | 3.4% | 2.9% | ||
| Q1 25 | 4.1% | 2.2% | ||
| Q4 24 | 4.3% | 9.0% | ||
| Q3 24 | 4.9% | 4.9% | ||
| Q2 24 | 2.2% | 4.6% | ||
| Q1 24 | 3.5% | 5.0% |
现金转化率AXONPODD
| Q4 25 | 79.14× | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | -2.54× | 8.73× | ||
| Q1 25 | 0.29× | 1.80× | ||
| Q4 24 | 1.84× | 1.47× | ||
| Q3 24 | 1.36× | 1.27× | ||
| Q2 24 | 2.03× | 0.51× | ||
| Q1 24 | -0.12× | 1.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXON
| Software And Sensors Segment | $342.5M | 43% |
| TASER Devices Professional | $264.2M | 33% |
| Personal Sensors | $109.1M | 14% |
| Platform Solutions | $80.9M | 10% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
